Linear polyethylenimine (L-PEI) is an efficient transfection agent for ovarian carcinoma cells in vitro and ex vivo. In the present work, we go a step further and evaluate the efficacy of L-PEI in human ovarian tumor nodes developed in mice. PEI/DNA complexes were administered intraperitoneally instead of intravenously to avoid sequestering of complexes in the lung and liver and to allow transfection of nonvascularized tumor nodes. Plasmid biodistribution was studied by PCR and gene expression was characterized using complementary luciferase and b-galactosidase assays. Intraperitoneal (i.p.) injection of L-PEI/DNA complexes allowed the straightforward distribution of plasmid in the whole peritoneal cavity. Gene expression occurred in many organs, but tumor nodes appeared as preferential sites for transgene expression. The i.p. delivery route allowed repeated injections and administration of large amounts of DNA (up to 400 mg) without signs of toxicity, even for doses well beyond the intravenous lethal dose. Transgene expression was dose-dependent and transient. However, multiple injections allowed its persistence to increase. These results provide encouraging elements towards the development of PEI-based gene therapy protocols for the treatment of advanced stage ovarian carcinoma.
Introduction
Cancer gene therapy using nonviral vectors is being regarded as a promising additive to conventional treatments. However, clinical trial reports using the first generation of vectors, that is, cationic lipids, highlight safety more than efficacy. The next generation, namely cationic polymers, is coming to maturity. Among them, polyethylenimine (PEI) is considered as the most effective. Preclinical data are available for hepatocellular carcinoma, 1 pancreatic tumors, 2, 3 ovarian carcinoma, 4, 5 head-andneck cancer 6, 7 and lung cancer. [8] [9] [10] More importantly, the first clinical data were published recently, which show dramatic bladder tumor remission in two patients. 11 Despite recent advances in chemotherapy, ovarian cancer remains the leading cause of death by gynecological malignancy in Western countries. The overall 5-year survival rate does not exceed 25%, mainly as a consequence of late tumor detection (after peritoneal dissemination) and chemoresistance following initial chemotherapy. Gene therapy might thus be an alternative or additive to the classic treatments. Protocols are based on the use of suicide genes such as the Herpes simplex thymidine kinase gene HSV-tk [12] [13] [14] [15] [16] [17] or on the re-establishment of wild-type p53 function. 18 In vitro results also show that other genes could be of interest for the treatment of ovarian cancer. 5, [19] [20] [21] [22] As a first step towards ovarian carcinoma gene therapy, we previously described the use of PEI derivatives, and particularly of Linear polyethylenimine (L-PEI) 22 kDa, for gene transfer to ovarian carcinoma cells in vitro and ex vivo. 4 The goal of the present work was to evaluate the efficiency of L-PEI on ovarian tumor nodes grown in nude mice. Distribution and histology were found close to those observed in human patients' carcinomatosis. In most cases, ovarian cancer dissemination is confined to the peritoneal cavity, suggesting local delivery as the preferred route of administration of the transgene. We further chose intraperitoneal (i.p.) administration of the DNA/PEI complexes to avoid retention of complexes in lung and liver as observed after intravenous injection. [23] [24] [25] We also expected i.p. delivery to reduce general toxicity, increase the local concentration of the transgene close to the tumor and allow transfection of nonvascularized nodes. Toxicity of the protocols was assessed by careful histological observation of each organ. Plasmid biodistribution was studied by PCR performed on total DNA collected from the different organs. Transfection was characterized globally, using a luciferase assay, and visually with a histochemical b-galactosidase assay.
Materials and methods

Nude mice
Female Swiss/nude 4-week-old mice were obtained from Charles-River Laboratories (L'Abresles, France) and maintained in a pathogen-free environment. Each of the 6-8-week-old animals was implanted intraperitoneally with 2 Â 10 7 ovarian adenocarcinoma SKOV3 cells and inspected and weighted daily. During the carcinomatosis characterization experiment, three mice were killed and dissected on days 7, 14, 21 and 28; the others were killed and autopsied when considered as moribund. Organs and tumors were fixed in formalin and paraffin-embedded for histological examination. Transfection experiments were performed 21 days after tumor implantation.
Cells
The SKOV3 cell line (derived from a human ovarian adenocarcinoma) was obtained from ECACC (Cerdic, Nice, France). Cells were grown in RPMI 1640 supplemented with 10% fetal calf serum, Glutamaxt I, 33 mM sodium bicarbonate, and 25 mM HEPES (Invitrogen, Lyon, France). They were maintained at 371C in a 5% CO 2 humidified atmosphere, and split twice a week by trypsinization.
Plasmids
The plasmid pCMV-Luc, encoding for the Photinus pyralis luciferase, was kindly provided by Dr B Demeneix (Museum National d'Histoire Naturelle, Paris, France). The pCMVLacZ plasmid encoding for b-galactosidase was obtained from Clontech (Palo Alto).
Polyethylenimine L-PEI was obtained from PolyPlus-Transfection (Illkirch, France) as an aqueous 100 mM solution in endotoxin-free water (in vivo jetPEI) and stored at À801C prior to use.
Complex formation and administration
JetPEIt/DNA complexes were prepared in 5% glucose solution with a ratio of L-PEI nitrogen to DNA phosphate of 5:1. Various amounts of DNA (50, 100, 250 or 400 mg) and L-PEI were diluted separately, and PEI was then added to the DNA. The solution was quickly homogenized and left for 15 min at room temperature. It was injected intraperitoneally in mice as a 1 ml 5% glucose solution.
Luciferase reporter gene expression assay Animals were killed 24 h, 72 h and 7 days after transfection and each organ (kidney, liver, spleen, pancreas, ovary, peritoneum, diaphragm, lung, heart and skeletal muscle) was washed with saline solution and split; parts of organs were either frozen in liquid nitrogen and stored at À801C for PCR and luciferase analysis, or fixed with formalin and paraffin-embedded for histological examination.
Luminometry
Luciferase activity was quantified using a Luciferase Assay System (Promega, Cergy Pontoise, France) as recommended by the manufacturer. Briefly, the frozen organs were resuspended in lysis buffer (Luciferase Assay System, Promega) and crushed using an Ultra-Turrax T25 (Janke & Kunkel, Germany). Cells were lysed by three freeze-thaw cycles and the cell lysate was centrifuged for 5 min at 10 000 r.p.m. at 41C to pellet debris. After centrifugation, the protein concentration was measured in duplicate in the supernatant by using the Bradford assay (Bio-Rad, Ivry sur Seine, France). Protein aliquots were stored at À801C before use. A volume of 20 ml of extract was mixed with 100 ml of luciferase assay substrate and luciferase activity was measured on a luminometer (Mediators PhL, Wien, Austria PCR detection of pCMV-Luc PCR analysis was used to evaluate the biodistribution of intraperitoneally injected DNA (pCMV-Luc) and the time course of its clearance.
The Dneasy Tissue Kit (QIAGEN, Courtaboeuf, France) was used to extract DNA from organs. DNA (1 mg) was subjected to PCR analysis using the primers previously described by Aoki et al.
0 ) and amplified under the following cycling conditions : preincubation at 941C for 5 min, then 941C for 1 min, 601C for 30 s and 721C for 2 min for 40 cycles and postincubation at 721C for 3 min. The PCR products were visualized on agar gel. Each experiment was performed on three mice.
b-Galactosidase assay b-Galactosidase activity was assessed using the b-galactosidase staining kit from Invitrogen (Lyon, France), either on frozen sections or on whole organs before paraffin embedding and histological observation. Paraffin sections (20 mm) were counterstained or not with eosin and hematoxylin, in order to visualize both b-galactosidase staining and histological structures.
Results
Establishment of a peritoneal carcinomatosis of human ovarian origin in nude mice
Intraperitoneal implantation of human ovarian adenocarcinoma SKOV3 cells led to the development of a peritoneal carcinomatosis with a tumor dissemination appearance very close to that observed in patients ( Figure 1a ). Histological examination showed that the tumor nodes organization was nearly undistinguishable from low-differentiated serous ovarian adenocarcinoma observed in women (Figure 1b ). SKOV3 cells are thus able, in vivo, to reconstitute three-dimensional structures with an architectural organization involving the constitution of a vascularized stroma of murine origin. Microscopic peritoneal dissemination appeared after 2 weeks of tumor development, became macroscopically visible after 3 weeks, and invaded the entire peritoneal cavity after about 1 month. The peritoneal wall, diaphragm, spleen and ovaries were the preferential sites of initial tumor growth, tumor nodes becoming voluminous and including all peritoneal organs thereafter, eventually leading to animal death.
This chronology allowed us to define two states of tumor development which find their equivalence in women; (1) a peritoneal microcarcinomatosis mimicking the situation observed after debulking surgery that may leave in place microscopic residues, thus leading to recurrence ( Figure 1a and c) ; (2) a whole peritoneum macroscopically spread carcinomatosis, including sometimes voluminous tumor nodes (Figure 1d ). In this part of our study, we worked only on the microcarcinomatosis stage, which is the most susceptible to gene therapy protocols in women.
Toxicity Mice received intraperitoneally 50, 100, 250, or 400 mg of pCMV-Luc complexed with jetPEIt as described in Materials and methods. No sign of toxicity was observed within the duration of the experiments (24 or 72 h), not even when the animals were killed after 7 days. At the highest DNA dose (400 mg), however, modifications of behavior were observed up to 2 h following injection (i.e. shocked appearance and reduced mobility); mice recovered a normal behavior thereafter. No tissue modification was observed after histological organ examination.
Biodistribution of the plasmid PCR analysis was performed on DNA extracted from various organs of tumor-bearing mice injected with L-PEI/DNA complexes prepared with either 50 or 100 mg pCMV-Luc.
It showed that L-PEI/DNA complexes had diffused throughout the peritoneal cavity and that the plasmid was not degraded 24 h after injection (Figure 2a ). Although PCR analysis is only semiquantitative, a dose-dependent relationship was observed between the amount of DNA and the band intensity, 100 mg DNA representing the optimal condition when this parameter was considered. Remarkably, the largest amounts of plasmid were detected in the spleen, pancreas, diaphragm and ovaries, which are also the preferential sites of tumor development in our model. The presence of a lower but significant quantity of plasmid in the lung and heart smooth muscle indicates that plasmid DNA is able to reach blood or lymph circulation or to use another transdiaphragm pathway to diffuse out of the peritoneal cavity.
Plasmid persistence in the organs was assessed by a second PCR analysis performed 72 h after injection in the same experiment (Figure 2b) . In this condition, the band intensity observed after 100 mg DNA injection decreased drastically, and the dose-dependence disappeared.
In order to counterbalance elimination or degradation of injected DNA, we repeated i.p. injections of jetPEIt/ DNA complexes. Three 100 mg DNA injections were performed within 36 h, followed by PCR analysis 24 h after the last injection (i.e. 60 h after beginning of the experimentation). In these conditions, we observed a plasmid distribution quite similar to that observed 24 h after a single injection of 100 mg DNA (Figure 2c ).
Luciferase gene expression
Luciferase enzyme activity was measured on lysates from the various organs and tumor nodes for all administration protocols. Luminometry and PCR analyses were performed on the same organs.
A control experiment with nontransfected SKOV3 tumor-bearing mice showed the background threshold to be 2 Â 10 2 RLU/mg of protein (Figure 3a) . Tumour-free mice At 20 h after injection of 50 mg of DNA, luciferase activity was detected only in the diaphragm and pancreas (3 Â 10 3 and 10 4 RLU/mg of protein, respectively). For the other organs, luciferase activity remained close to the background. In contrast, when 100 mg of DNA was injected, all organs of the peritoneal cavity except the kidneys showed luciferase activity levels between 10 3 and 4 Â 10 4 RLU/mg of protein. Outside, luciferase activity was detected in the heart, but not in the lungs under these conditions (Figure 3b ). Luciferase activities drastically fell 72 h after injection (Figure 3c) .
On the contrary, in the case of the multiple injections protocol, high luciferase activity was still detected 60 h after the first injection (Figure 3d ). This administration protocol increased both the duration and the level of luciferase expression in nearly all peritoneal organs (3 Â 10 3 to 5 Â 10 5 RLU/mg of protein 60 h after the first injection). The highest activity was detected in the tumor nodes and diaphragm.
In agreement with the pattern of plasmid distribution as revealed by PCR, luciferase activity was higher in the tumor nodes and in the diaphragm, peritoneal wall, spleen and ovaries, which are preferential sites for tumor dissemination, as observed earlier. Moreover, the control mice that had not received tumor cells but had received PEI/pCMV-Luc complexes presented much weaker luciferase activity (Figure 3e ).
We were generally unable, after 21 days of tumor development, to physically separate tumor nodes from the associated organs. In order to specifically study the transfection of tumor nodes, we performed similar experiments after 35 days of tumor development. In these conditions, we obtained larger tumor nodes (about 2-5 mm diameter) on which luciferase assay could be performed. Our results showed that these tumor nodes presented luciferase activity 24 h after DNA injection, and that increasing the amount of DNA over 100 mg (i.e. 250 and 400 mg) does not represent a benefit in terms of luciferase activity per mg of tumor protein (Figure 3f ).
b-Galactosidase gene expression b-Galactosidase activity was assessed using a colorimetric enzyme assay. Both macroscopic and histological observations showed that b-galactosidase activity was present in tumor nodes developed in nude mice, even in the deeper layers of cells (Figure 4) . Such results have been obtained with a single injection of 250 mg DNA as well as with the multiple injections protocol (3 Â 100 mg). In other cases (100 mg of DNA), no macroscopic b-galactosidase staining could be observed.
Discussion
Despite advances in surgical techniques and the recent introduction of new therapeutic agents, epithelial ovarian carcinoma has had no significant improvement of overall survival rate over the last two decades. As a consequence, it is a preferred candidate for experimental cancer gene therapy. Numerous approaches have been developed recently that test new strategies (see DiSaia and Bloss 26 for a review). However, the development of a new therapeutic strategy requires not only identification of the target, but also choosing a suitable vector and optimal administration route. In the present report, we address this last question, and present results of i.p. administration of L-PEI-complexed DNA expressing reporter gene in mice bearing human ovarian tumor xenografts.
Nonviral vectors fall into two classes of molecules that are able to condense DNA into cationic particles. Cationic lipids can be very efficient for transfection of cells in culture, but aggregation of the corresponding DNA particles and marked instability towards serum proteins led to disappointing in vivo results. Cationic polymers represent a more recent, second generation of vectors, which can be formulated with DNA into stable nanoparticles that withstand serum proteins. Among them, L-PEI was chosen for its ability to lead to robust transgene expression in vivo following various administration routes. 2, 3, [23] [24] [25] [27] [28] [29] Moreover, it has been previously demonstrated that linear PEI is more efficient than the branched polymer in vitro and in vivo, 4, 30, 31 and Figure 4 b-Galactosidase activity in tumor nodes developed on the peritoneal wall of mice transfected with 100 or 250 mg DNA, evaluated 24 h after injection as described in Materials and methods.
Intraperitoneal PEI-mediated gene delivery M-H Louis et al cationic lipids. 31,32 L-PEI is also known to efficiently transfect ovarian carcinoma cells. 4 Our first objective was to establish a tumor model taking into account the tridimensional organization of tumors and environmental elements encountered in vivo. We thus injected SKOV3 ovarian carcinoma cells intraperitoneally in nude mice, and obtained a pertinent model of ovarian peritoneal carcinomatosis, in which both tumor dissemination and histology appear closely related to those observed in the clinical situation.
The second objective of our work was to determine optimal conditions leading to gene delivery into our in vivo tumor model. Different amounts of DNA formulated with L-PEI were administrated. After i.p. administration of DNA/PEI complexes, we did not observe any sign of toxicity, even for the highest dose (400 mg of DNA), though the Lethal Dose 100 in Swiss nude mice is 100 mg DNA when injected intravenously in similar conditions. 23 We studied plasmid biodistribution using PCR analysis. Our results show that 24 h after injection, the plasmid was distributed among the different organs of the peritoneal cavity, with little retention in the lung and liver, contrary to the situation observed after intravenous injection. 33, 34 To a lesser extent, DNA was also found in the lung, heart and smooth muscle. This observation has been previously reported by Aoki et al, 2 after i.p. injection of L-PEI in pancreatic-tumor-bearing mice. It is noticeable that the amount of plasmid retained by the different organs appeared to be dose-dependent. This suggests, first, that the saturation phenomenon did not occur in our experimental conditions, and second, that in the case of a 50 mg DNA injection, the L-PEI/DNA complexes could be trapped by free polyanions, for instance, and could not reach the organs.
The plasmid persistence was short in our experiments, since only very low amounts of DNA remained detectable after 72 h, indicating probable degradation and clearance. As a way to increase transgene persistence, multiple injections of 100 mg complexed DNA were performed. In this case, the transgene was still detected in great amount 60 h after the first injection. These results show that multiple injections of L-PEI/DNA complexes are possible without any associated side effect. Such protocols could be particularly interesting when long-term persistence of the expression is needed.
The presence of the plasmid was correlated with the transgene expression. Luminometry analysis showed that delivery of L-PEI/DNA complexes led to transgene expression in various organs (diaphragm, peritoneal wall, spleen, pancreas and ovaries) as well as in tumor nodes where the expression level was maximum. Furthermore, rough dose-and time-dependence of both phenomena were similar. The use of the b-galactosidase reporter gene with histochemical X-gal staining in order to show where transgene expression occurs in tumor nodes demonstrated that tumor nodes were preferential sites for intense transgene expression and normal surrounding tissues only poorly expressed the transgene. b-Galactosidase activity was detected in mice injected with 250 mg or 3 Â 100 mg DNA, whereas luciferase activity was detected in mice injected with lower amounts of DNA. This could be a consequence of the lower sensitivity of X-gal staining as compared to luminescence assay, as previously suggested in vitro. 2, 4 After i.p. injection, the transgene expression profile is completely different from that observed after intravenous injection, in which the lung, liver and kidney appear as preferential expression sites, [23] [24] [25] probably as a consequence of their filtration function. The plasmid diffusion and distribution thus appears noticeably different after i.p. injection, since it seems preferentially accumulated in tumor and tumor-bearing tissues. This relative selectivity and passive targeting could be linked only to a particular susceptibility of tumor nodes, perhaps due to the particular organization or tumor tissue or to a possible difference in the expression of surface molecules such as heparan sulphate.
No luciferase activity was detected in the kidney, irrespective of the experimental procedure employed. This observation has been also reported by Aoki et al 2 , and is the sign of a strong peritoneal barrier. Although the putative protective effect of peritoneum was less visible on other organs, it could be, at least in part, responsible for the preferential transfection observed for the diaphragm and pancreas (which present, in both cases, a great surface of peritoneum), and tumor (that is not covered by peritoneum). This could constitute a key factor for passive tumor targeting, i.p. delivery thus being a means to increase specificity of transfection and to decrease the extent of associated side effects.
In summary, i.p. injection of L-PEI/DNA complexes allows gene transfer in mice without toxicity. Gene expression is preferentially observed in tumors as compared to normal tissues. The transient character of gene expression could be overcome by multiple injections. These results provide encouraging elements towards the development of PEI-based gene therapy protocols for the treatment of advanced stage ovarian carcinoma.
